In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Sending letters to encourage guideline-directed practice in the management of chronic kidney disease to either patients or ...

A spirited pro/con debate at ERA 2025 explores whether population-level albuminuria screening could improve early CKD detection, with feasibility, cost-effectiveness, and equity all weighed.

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Doctors and researchers are exploring various approaches to tackle this pervasive health issue, from new medications to dietary interventions. But what if one of the most promising treatments relies ...

During a session at the Heart in Diabetes CME Conference, speakers highlighted four papers recently published in Circulation ...

BEIJING--(BUSINESS WIRE)--Novo Holdings, a leading global life science investor, and KKR, a leading global investment firm, today announced the signing of definitive agreements under which Novo ...